For BMS, Onglyza Disappoints And Health Care Reform Takes A Toll
This article was originally published in The Pink Sheet Daily
Executive Summary
The health care reform law, which will lower Bristol-Myers Squibb's sales by $350 million to $400 million this year, led the firm to revise earnings guidance.
You may also be interested in...
Novo Nordisk's GLP-1 Victoza Off To A Good Start
New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.
340B Entities Will Continue Fighting For Inpatient Drug Discounts
Issue is a top priority for Safety Net Hospitals for Pharmaceutical Access; provision to extend discounts to inpatient drugs was deleted from final health care reform bill.
J&J Braces For Health Care Reform Hit, But Can "Accommodate" Impact
J&J's 2010 sales will be $400 million to $500 million lower due to health care reform, although J&J didn't significantly lower 2010 earnings as a result.